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The high-quality adjusted case series by Saratzis et al1 puts another strong 
counterargument to the Paclitaxel-increases-mortality debate started by the meta-
analysis from Katsanos et al in 2018.2 The reaction to that meta-analysis was 
unprecedented in recent times, halting international practice despite widespread 
adoption of the technology and derailing randomised trials.  
 Saratzis et al examined a series of 2,071 patients with claudication or Chronic 
Limb Threatening Ischaemia (CLTI) and found that there was no excess mortality in 
the group receiving Paclitaxel after careful confounder adjustment.1 The usual quality 
arguments against this approach apply in that it is retrospective data with inherent 
biases. However the authors have done their best to statistically adjust for these, and 
importantly, have a relatively high event rate for their primary outcome (death) 
because of a 50% proportion of patients with CLTI. Different but equally valid quality 
arguments can be applied against the low-quality trials included in the Katsanos 
analysis which included a predominance (90%) of patients with claudication, a lower 
subsequent event rate for death, and were underpowered to report accurately on 
mortality. Long-term follow up from a local dataset is always challenging as 
accurately determining whether a patient is alive or dead is often unclear after the 
last local follow up. Without truncated follow up at a clear event such as a scan or 
clinic appointment, or data linkage to a validated dataset, morality reporting may be 
unreliable. While the quality of truncated follow up in the Saratzis study is unclear, 
the trials in the Katsanos analysis suffer from the same follow up problem. 
Additionally, none of the studies in the Katsanos analysis were designed for 5-year 
mortality comparisons and ascertainment bias in mortality assessment was likely. 
This is evidenced by the decrease in the mortality signal with longer term patient 
follow-up from the included studies, as well as the lack of a signal in the Japanese 
IMPACT trial, with more complete follow up data.3  
 Saratzis et al’s study adds to previously published large cohort analyses 
examining the effect of Paclitaxel devices on mortality.4-6 Mortality rates were found 
to be similar, or even less, with Paclitaxel-eluting endovascular technologies in these 
studies based on large, validated administrative databases with reliable information 
on all-cause mortality and on co-morbidities.4-5 With over 60,000 patient, robustly 
adjusted cohort data showing no problem with Paclitaxel devices and strong 
arguments against the quality of included studies in the Katsanos analysis of 5000 
patients (with only 1429 included in the 5-year mortality analysis), where are we now 
in the Paclitaxel-increases-mortality debate? The answer is that there was highly 
likely to be confounding and bias in the studies included in the Katsanos analysis.  
The remaining problem is the signal towards mortality from each of the 
included studies in Katsanos analysis. It has been argued that these can only 
‘definitively’ be proved as a cluster by a large randomised trial. It’s just as well these 
have managed to start recruiting again. 
 




1. Saratzis A, Lea T, Yap T, Batchelder A, Thompson B, Saha P, 
Diamantopoulos A, Saratzis N, Davies R, Zayed H. Paclitaxel and mortality 
following peripheral angioplasty: an adjusted and case matched multi-centre 
analysis. Eur J Vasc Endovasc. In press.  
2. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of 
Death Following Application of Paclitaxel-Coated Balloons and Stents in the 
Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of 
Randomized Controlled Trials. J Am Heart Assoc. 2018;7(24):e011245. 
3. Iida O, Soga Y, Urasawa K, Saito S, Jaff MR, Wang H, Ookubo H, Yokoi H; 
MDT-2113 SFA Japan Investigators. Drug-coated balloon versus uncoated 
percutaneous transluminal angioplasty for the treatment of atherosclerotic 
lesions in the superficial femoral and proximal popliteal artery: 2-year results 
of the MDT-2113 SFA Japan randomized trial. Catheter Cardiovasc Interv. 
2019;93:664-672 
4. Behrendt CA, Sedrakyan A, Peters F, et al. Long Term Survival after 
Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A 
Propensity Score Matched Cohort Analysis [published online ahead of print, 
2020 Jan 8]. Eur J Vasc Endovasc Surg. 2020;S1078-5884(19)32708-X.  
5. Secemsky EA, Kundi H, Weinberg I, Jaff MR, Krawisz A, Parikh SA, Beckman 
JA, Mustapha J, Rosenfield K, Yeh RW. Association of Survival With 
Femoropopliteal Artery Revascularization With Drug-Coated Devices. JAMA 
Cardiol. 2019;4:332-340. 
 
 
 
